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IPF and fibrotic NSIP (fNSIP) belong to the idiopathic interstitial pneumonias and are usually
fatal, but fNSIP has a better outcome. In order to identify molecular mechanisms and
differences between IPF and fNSIP, we herein present results of a comparative proteome
analysis of IPF, fNSIP and control lung tissue. Our data including validation experiments
suggest that ER stress and a general stress-response as well as the decline of antioxidant
capacity in alveolar epithelium is key in the pathogenesis of IPF and fNSIP. In addition, we
could observe a signature of an increased alveolar epithelial protection against oxidative
and ER-stress in fNSIP as compared to IPF, which could help to explain the better outcome
of fNSIP patients.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The idiopathic interstitial pneumonias (IIPs) are a heterogenous
group of diffuse parenchymal lung diseases of unknown
etiology, which are characterized by distortion of distal lung
architecture by variable inflammation and fibrosis [1]. Of the
IIPs, idiopathic pulmonary fibrosis (IPF) and nonspecific inter-
stitial pneumonia (NSIP) have provokedmost attention and also
debate. Although IPF andNSIP can present in a clinically similar
manner, it is currently accepted that they are different diseases,
especially with respect to prognosis [1,2]. IPF, histologically
defined by the usual interstitial pneumonia (UIP) pattern, is a
disease in individuals aged 50 to 60 years and occurs somewhat
more frequently in men [3–5]. UIP is characterized by dense
fibrosis that causes destruction of the alveolar architecturewith
frequent honeycombing and bronchiolization of the alveoli,
scattered fibroblast foci, and patchy lung involvement. At low
magnification, the lung characteristically has a heterogenous
appearance with alternating areas of normal parenchyma,
fibrosis, and (bronchiolized) honeycomb cysts [1,3,4].
NSIP patients tend to be approximatively 10 years younger
than IPF subjects, are more frequently female and may be
sub-differentiated into cellular (cNSIP) and fibrotic NSIP
(fNSIP) [1,2,5–7]. The histology of NSIP is temporally uniform,
without the spatial and temporal heterogeneity of UIP. When
NSIP is predominantly cellular, chronic interstitial inflammation
involves the alveolar walls. In fNSIP, fibrosis consists of uniform
collagen accumulation, resulting in expansion of alveolar septa
and peribronchiolar interstitium without the patchwork distri-
bution of UIP. Honeycombing and fibroblastic foci are rare [2,5].
Regarding prognosis, the average survival time in IPF from
time of diagnosis is 2–3 years, due to the quite aggressive course
of this disease [1,3,4]. In marked contrast, cNSIP appears as a
rather benign disease with slow progression. Patients with
cNSIP usually show a good response to steroid treatment, and
an only modest limitation in life expecting [8,9]. The prognosis
of patients with fNSIP seems to be in between IPF and cNSIP [5].
It has also been suggested that IPF/UIP simply represents a late
presentation stage of untreated (or poorly responsive) NSIP
[10,11].With regard to therapy, pirfenidone has been authorized
for treatment of mild to moderate IPF only [12], and steroid/
immunosuppressive therapy has recently found to be ineffi-
cient in this disease [13]. In contrast, steroids/immunosuppres-
sants seem to work in cNSIP, but not in fNSIP [8].
In summary, despite the prognostic and therapeutic
implications, it is often clinically difficult to distinguish IPFfrom fNSIP, and, in absence of a definite UIP pattern in HRCT,
surgical lung biopsy is still considered as diagnostic gold
standard for both disorders [1–4]. Therefore, there is a great
need for surrogates for diagnosis of both fatal diseases.
The molecular pathomechanisms underlying IPF and NSIP
are incompletely understood, with most studies being done in
the field of IPF. According to these, IPF is thought to be the result
of a chronic injury to the alveolar epithelium, with continueous
activation of aberrant repair processes and consecutive replace-
ment of alveolar architecture by fibrotic scars and cysts lined
by abnormal bronchiolar epithelium [14–17]. In line with this,
apoptosis of type-II alveolar epithelial cells (AECII) is a promi-
nent finding in IPF [18–22], but has also been observed in
patients with exogen allergic alveolitis (EAA), cNSIP and fNSIP
[23,24]. Such observation is supported by the finding of SP-C
gene mutations in familial forms of IIP (mostly IPF and NSIP),
which have been shown to result in the production of abundant
misfolded proproteins, causing proteasome inhibition and
endoplasmic reticulum (ER) stress, and finally, death of the
AECII [25–27]. Moreover, proapoptotic ER stress in AECII is also a
prominent feature in patients with sporadic IPF in the absence
of any genemutation [28]—and doesnot seem to differ in extent
from familial IPF cases [29]. With regard to NSIP, however, data
are much more scarce. According to our own preliminary
studies, the extent of the proapoptotic ER stress response in
AECII may almost be identical in fibrotic NSIP as compared
to IPF [30]. However, the precise trigger mechanisms that
culminate in ER stress, and AECII cell death are still unknown
and molecular signatures and pathways that distinguish
(fibrotic) NSIP fromUIP remainelusive. To this end, comparative
gene expression profiling in patients with UIP and NSIP
(both: cNSIP and fNSIP) showed that there are consistent,
but only few significant differences between the two types of
IIP at the transcriptional level [10,11,31]. However, the lung
proteomic patterns of the different types of IIP have yet not
received attention. We hypothesized that IPF and fNSIP
may exhibit different proteome signatures that may be useful
to distinguish both entities, hence allowing development of
new, disease-specific biomarkers and detection of molecular
pathomechanisms/signatures that underlie the distinct lung
phenotypes in IPF and fNSIP. We therefore performed a
comparative proteome analysis of subpleural lung tissue from
patientswith sporadic IPF and fNSIP,with explanteddonor lungs
serving as controls. We employed the 2-Dimensional Difference
in Gel Electrophoresis (2D-DIGE) approach, which allows the
simultaneous co-separation of multiple, fluorescently labelled
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to remove gel-to-gel variation, thereby significantly increasing
accuracy and reproducibility. The present study reports the
separation and comparison of the IPF-, fNSIP- and healthy
control lung proteome on one and the same 2D-gel, and reports
the validation and cellular localization of specifc proteomic
signatures in all categories. To our surprise, the proteomic
profiles of IPF and fNSIPwerequite similar andonlydifferedwith
regard to subunits of the proteasome activator complex and
antioxidant enzymes, and cytokeratin-19.2. Material and methods
2.1. Human lung tissue
Lung tissue samples were obtained from 14 patients with IPF
(UIP pattern; mean age ± SD: 54.29 ± 14.40 years; 4 females, 10
males), 8 patients with fibrotic NSIP (fNSIP; mean age ± SD:
51.25 ± 8.52 years; 5 females, 3 males), and 10 control subjects
(organ donors; mean age ± SD: 46.20 ± 18.25 years; 5 females, 5
males). Explanted lungs or lobeswere obtained from the Dept. of
Thoracic Surgery, Vienna (W. Klepetko). Already at the surgical
theatre, peripheral lung tissue samples were snap-frozen or
placed in 4% (w/v) paraformaldehyde immediately after explan-
tation. Thereafter, the remaining lung lobes were placed on ice,
and shipped (together with the other samples) to our institute
immediately. Upon arrival, lung lobes were sectioned under the
hood on ice according to a predefined algorithm; and additional
lung tissue samples from subpleural and hilar regions were
placed in 4% (w/v) PFA or snap-frozen in liquid nitrogen. The
latter samples were stored at −80 °C until used.
Retrospectively, the diagnosis of IPF or fNSIP was reviewed
and validated by A. Guenther and an expert pathologist (L. Fink)
using current American Thoracic Society/European Respiratory
Society (ATS/ERS) guidelines [1–4], and patients were included
only when current ATS/ERS criteria were met. The study
protocol was approved by the Ethics Committee of the
Justus-Liebig-University School of Medicine (No. 31/93, 84/93,
29/01). Informed consent was obtained in written form from
each subject for the study protocol. Demographic and clinical
data (lung function test parameters) on donor subjects or
patients receiving transplantation in Vienna are summarized
in Table 1 (upper panel).
2.2. Human bronchoalveolar lavage fluid (BALF)
Next to lung tissues, bronchoalveolar lavage fluids (BALF) were
collected fromadditional patientswith sporadic IPF (n = 6;mean
age ± SD: 65.83 ± 13.48 years; 1 female, 5 males), sporadic
fibrotic NSIP (fNSIP, n = 7; mean age ± SD: 61.14 ± 21.25 years; 3
females, 4 males) at the time of first diagnosis as well as from
six healthy volunteers (HV, n = 6; mean age ± SD: 31.67 ±
16.95 years; 4 females, 2males) in theDept. of InternalMedicine,
Giessen (A. Guenther). All subjects with IIP underwent bron-
choscopy for diagnostic purposes. Flexible fiberoptic bronchos-
copy was performed in a standardized manner as previously
described [32]. One segment of the lingual or the right middle
lobe was lavaged with a total volume of 200 mL sterile saline in10 aliquots. The fractions were pooled, filtered through sterile
gauze, and centrifuged at 200 ×g (10 min, 4 °C) to remove cells
and membranous debris. Aliquots of the cell-free BALF super-
natant were stored at −80 °C. These patients undergoing
BAL had not previously been treated with steroids or other
immunosuppressants. Finally, a UIP—or fibrotic NSIP pattern
was proven in all IPF—and NSIP subjects, because all of them
later underwent video-assisted thoracic surgery (VATS) for
diagnostic purpose. IIP-patients and HV gave their written
informed consent to the study, and the local Ethics Committee
approved the study. Demographic and clinical data (lung
function test parameters) of these subjects are summarized in
Table 1 (lower panel).
2.3. Sample preparation for two-dimensional gel analysis/
DIGE technique
For the proteome analysis, peripheral lung tissue samples from
the lower lobe, from the subpleural region of the lungwas used.
Frozen lung tissue samples (size 1 cm3) from IPF-, fNSIPpatients
and controls were homogenized in extraction buffer, as
described previously [33]. Crude lung extracts were centrifuged
at 10,000 ×g for 10 min at 4 °C to remove cell debris. The protein
concentration in each supernatant lung homogenate was
determined according to the BCA protein assay from Perbio
Science. Thereafter, equal masses of total protein (0.5 mg) of
each individual IPF-, fNSIP- or control homogenatewere pooled,
respectively.
For isoelectric focusing (IEF), proteinswere then precipitated
with acetone (80% final concentration). After brief air drying in
the hood, precipitated proteins of the IPF-, fNSIP- and control
pool were resolubilized using a rehydration buffer containing
7 mol/L urea, 2 mol/L thiourea, 0.5% (v/v) pharmalyte buffer for
commercial pH4–7 and pH6–11 linear IPG strips (GEHealthcare,
Uppsala, Sweden), 4% (w/v) CHAPS and 20 mmol/L Tris. The
concentration was adjusted for all pools to approx. 1.5 μg/μL.
The resulting protein samples (in a volume of 2 mL)were frozen
at −80 °C. The consecutive DIGE-proteome analysis was then
undertaken with the help of TOPLAB GmbH, a proteomics
company (Martinsried, Germany). In brief, the protein concen-
tration in each pool was again determined by a commercially
available kit. Thereafter, 50 μg proteins of each pool were
labelled with 400 pmol of different CyDye fluorophors (IPF:
Cy3, fNSIP: Cy5, control lungs: Cy2). The Cy2-, Cy3- and
Cy5-labelled samples were subsequently combined and
separated by using Two-dimensional gel electrophoresis
(2D-PAGE). The separation was carried out on Multiphor™ II
(GE Healthcare) in the first dimension (IEF electrophoresis,
pH 4–7), followed by equilibration and reduction of IEF-strips
according to standard protocols. Focused IPG gel strips were
then loaded on top of SDS-polyacrylamid gels (13% total
acrylamide, 3% bisacrylamide), and the second dimension
electrophoresis was carried out using a Hoefer-ISO-DALT
vertical gel electrophoresis system (GE Healthcare) according
to standard procedures. The resulting 2D-DIGE-gel representing
three different proteomes was performed in duplicate. It has to
be noted that we did not perform the classical DIGE procedure
by preparing an internal standard (pool of all samples) labelled
with Cy2; instead, the control lung protein pool was labelled
with Cy2 and served as the healthy, normal reference lung
Table 1 – Selected demographic and clinical data on study subjects.
Explanted lung tissues Organ donors (n = 10) Sporadic IPF/UIP (n = 14) Sporadic fNSIP (n = 8)
Mean age (yr ± SD) 46.20 ± 18.25 54.29 ± 14.40 51.25 ± 8.52
Gender (m/f) 5/5 10/4 3/5
FVC, % predicted (mean ± SD) n.a. 58.41 ± 12.54 50.7 ± 22.29‡
FEV1, % predicted (mean ± SD) n.a. 63.28 ± 9.47 47.1 ± 19.48‡
Smoking status: current/former/never n.a. 0/7/7 0/1/6‡
PY (mean ± SD) n.a. 37 ± 25 n.a.
Bronchoalveolar lavage fluids (BALF) Healthy volunteers (HV, n = 6) Sporadic IPF/UIP (n = 6) Sporadic fNSIP (n = 7)
Mean age (yr ± SD) 31.67 ± 16.95 65.83 ± 13.48 61.14 ± 21.25
Gender (m/f) 2/4 5/1 4/3
FVC, % predicted (mean ± SD) 97.88 ± 8.59 68.92 ± 13.30†, § 60.60 ± 13.64§
FEV1, % predicted (mean ± SD) 103.15 ± 11.49 77.28 ± 11.93†, § 65.25 ± 17.17§
%DLC0/SB, % (mean ± SD) 86.06 ± 11.77† 39.14 ± 11.77†, § 54.20 ± 10.64⁎, §
Smoking status: current/former/never 0/0/6 0/3/2† 0/2/5
PY (mean ± SD) – 10 ± 14 2 ± 3
Definition of abbreviations: IPF = idiopathic pulmonary fibrosis; UIP = usual interstitial pneumonia; fNSIP = fibrotic non-specific interstitial
pneumonia; BALF = Bronchoalveolar lavage fluid; FVC = forced vital capacity; FEV1 = forced expiratory volume after 1 s; %DLCO/SB = ratio of
diffusing capacity for carbon monoxide, single breath; PY = pack years; n.a. = not available.
‡ = In these cases, data were available from 7 individuals; † = In these cases, data were available from 5 individuals; * = p < 0.05 vs. IPF; § = p < 0.01
vs. HV.
With regard to explanted lung tissues, no data were available for DLCO/SB.
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proteomes on one 2D-gel we chosed this strategy.
2.4. Image analysis of two-dimensional-DIGE-gels
After 2D-PAGE, gelswere scannedwith 100 μmresolution using
the EttanTM DIGE Imager. Excitation wavelengths and emission
filters were chosen specifically for each of the CyDyes, and
images with DIGE readouts Cy2, Cy3 and Cy5 were recorded
(Supplementary Fig. E1).
Computer-assisted analysis of imaged 2D-gels/DIGE read-
outs was performed with Proteom Weaver Software (v 3.0.0.3,
BioRad, Munich, Germany). In brief, spot detection, matching
of protein/peptide spots between gels and different readouts
(“in-gel spot-codetection”), as well as background subtraction
and normalization etc. were carried out by the software using
standard settings. Individual spot intensities were calculated
by the software. For the comparative analysis of the different
CyDye labelled lung proteomes, three distinct overlays of the
respective readouts were performed (Control-Cy2/IPF-Cy3,
Control-Cy2/fNSIP-Cy5 and fNSIP-Cy5/IPF-Cy3). The spots
qualifying for differential protein expression had the following
criteria: correct positioned matching in all gels and readouts,
expressed with 95% statistical confidence (p-value < 0.05, un-
paired Student´s t test). Additionally, for the comparison of the
IPF- and the fNSIP-proteomewith regard to the control proteome,
protein spots were considered as differentially regulated if the
-fold change value (quotient of corresponding group means of
spot intensities, also designated as regulation factor RF) between
the IPF- and the control group, as well as between the fNSIP- and
control group, was ≥1.5 (for 1.5-fold or more upregulation) or
≤0.75, (for 1.5-fold or more downregulation). The same criterion
was used for the comparison of the fNSIP-proteome with regard
to the IPF-proteome. The criterionmeaning a ≥1.5-fold change in
expression between the comparison groups was chosen, due to
the relative low number of differentially regulated proteinsfulfilling a 2.0-fold change (especially the downregulated
proteins), and because there was nearly no spot revealing two-
fold or more differential regulation in the comparison fNSIP
versus IPF. For an overview, scatterblotswereperformed inwhich
the intensities of the “matched” protein spots in the respective
overlays were compared (IPF-Cy3 versus Control-Cy2, fNSIP-Cy5
versus Control-Cy2 and fNSIP-Cy5 versus IPF-Cy3) [see Supple-
mentary Figs. E2 and E3] using the “default setting”. The
scatterblots for the comparisons IPF-Cy3 versus Control-Cy2
[Suppl. Fig. E2A] and fNSIP-Cy5 versus Control-Cy2 [Suppl. Fig.
E2B] indicated evidently similar amounts of differentially regu-
lated proteins in both entities with regard to the control
proteome. Interestingly, in the comparison fNSIP versus IPF,
only a sparse amount of protein spots revealed differential
regulation (Suppl. Fig. E3). The spot quantities and regulation
factors for the comparison IPF and fNSIP versus control group are
summarized in Supplementary Table E1, and these for the
comparison fNSIP versus IPF in Supplementary Table E2.
Due to low abundance of differential regulated protein
spots in 2D-DIGE-PAGEs, micropreparative 2D-PAGE´s using
600–1000 μg lung proteins (from the fNSIP pool or from a 1:1
mixture of the fNSIP pool with the control lung pool, both
“mixtures” contained wholly all differential regulated protein
spots identified by DIGE-image analysis) were performed and
stained with coomassie, in order to guarantee enough protein
content for the identification by MALDI-TOF-MS.
2.5. Protein digestion and MALDI-TOF-MS analysis
In brief, the selected spots were excised and trypsin digested
according to standard protocols. Prior to digestion, the proteins
were destained using 50 mM (NH4)HCO3 in 30% acetonitrile.
In-gel digestion was performed overnight with 0.05–0.15 μg
trypsin sequencing grade (Roche Diagnostics, Mannheim,
Germany 2006, Serva 2011) in 10 mM (NH4)HCO3. The resulting
peptide mixture was desalted using μ C18 ZipTips (Millipore,
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Then the desalted peptidemixturewas spotted onto a stainless
steel target (AB Sciex) using the dried droplet method with the
matrix alpha-cyano-4-hydroxy cinnamic acid. The peptides on
the target were measured with a MALDI mass spectrometer
(4800 Proteomics Analyzer, AB SCIEX, Foster City, CA, USA). The
spectrum was acquired in the mass range of 700–4.500 m/z
(2006: 600–4.200 m/z) with the instrument operating in reflec-
tion mode.
The raw spectra were processed with the Data explorer
(version 4.3.; AB Sciex) software. All spectra were externally
calibrated using a peptide calibration standard (AB Sciex
2006, Bruker 2011). Database queries of the monoisotopic
masses were performed with the search engine ProFound
(prowl.rockefeller.edu), which uses the Bayesian probability to
identify unknown sequences against a protein sequence data-
base. ProFound takes into account individual properties of each
protein in the database as well as other information relevant to
the experiment such as the mass range in which the protein is
expected to lie (this information can be taken from 2D-gel).
The sequence database to be searched was the NCBI non-
redundant database (the version released in Sep. and Nov. 2007,
and Feb. 2012). The taxonomic category was “Homo sapiens
(human)” (119130 sequences). The other search parameterswere
Mr ranges within ±25% of measured values, pI range from 0.0 to
14.0, monoisotopic peptide masses, one missed cleavage by
trypsin, complete modifications: iodoacetamide-C, partial mod-
ifications: oxidation (M), charge state: MH+, and mass accuracy:
100.00 ppm. The criterium used for a positive identification
was a significant Z-score (Est´dZ) with the probability score
1.0e+000. To date, proteins reaching a ProFound score ≥1.65
are considered as significant at the 5% level (P < 0.05). Of
the databases for peptide mass fingerprints (PMFs), Mascot and
ProFound have been shown to clearly separate the correct
identifications from the randommatches.
The PMFmass spectra and protein identification results of the
proteins identified in this study are shown in Supplemental Figs.
S1 to S36; includingMS-peak list, Z-score, the number of peptides
matched to the identified protein from the total of peptides
submitted, the sequence coverage, theoretical MW and pI of the
identified protein, and the mass tolerance of matched peptides.
2.6. Immunohistochemistry (IHC)
Human lungs were placed in 4% (w/v) paraformaldehyde after
explantation (fixation was done for 12–24 h), and processed for
paraffin embedding. Sections (3 μm) were cut, mounted on
positively charged glass slides (Super Frost Plus, Langenbrinck),
and subjected to antigen retrieval by cooking the sections in
10 mmol/L sodium citrate (pH 6.0) as previously described [33].
Proteins of interestwere visualized using theZytoChem-PlusAP
Kit (Fast Red) or ZytoChem-Plus HRP Kit (DAB-staining, brown
dye), Broad Spectrum (Zytomed Systems, Berlin, Germany)
according to protocols of the manufacturer. In the following,
the primary antibodies used for IHC are listed, including the
sources and dilutions: rabbit polyclonal for human proSP-C
(1:750, Millipore), rabbit monoclonal for cytokeratin-5 [KRT5]
(1:200, abcam), rabbit polyclonal for human PPIA (1:100, Santa
Cruz Biotechnology Inc.), mouse monoclonal for human LAP3
(1:100, Santa Cruz B. I.), rabbit polyclonal for human PSME1/PA28α (1:500, Calbiochem), rat monoclonal for human clara
cell-protein 10 [CC10] (1:75, R&D Systems), mouse monoclonal
for human FoxJ1/HFH4 (1:75, Abcam), rabbit polyclonal for CD68
(1:200, Abcam), rabbit polyclonal for human Prdx1 (1:800, Abcam),
rabbit polyclonal for humanATF6/p50ATF6 (1:100, Abcam), rabbit
polyclonal for human XBP1 (1:50, Santa Cruz B. I.), mouse
monoclonal for human Prdx6 (1:1000, Abcam) and rabbit poly-
clonal for cytokeratin-19 [KRT19] (1:100, Abcam). Control sections
were treated with PBS or with rabbit or mouse primary antibody
isotype control (Acris Antibodies GmbH, Hiddenhausen,
Germany) to determine the specificity of the staining.
Lung tissue sections were scanned with a Mirax Desk slide
scanning device (Mirax Desk, Zeiss, Göttingen, Germany), and
examined histopathologically at 100×, 200× and 400× original
magnification. IHC for mentioned antibodies was undertaken
in 10 IPF-, 5 fNSIP- and 8 control lung samples.
2.7. Quantitative Western Blot analysis of human BALF
and statistics
The protein concentration in BALF was determined according
to the BCA protein assay from Perbio Science, followed by
concentration of BALF samples to 5 or 10 μg lavage protein per
case using a SpeedVac concentrator. Samples were then each
dissolved in 20 μL of SDS-sample buffer (final concentration 2%
(w/v) SDS, 2.5% (v/v) β-mercaptoethanol, 10% (v/v) glycerol,
12.5 mmol/L Tris–HCl [pH 6.8], 0.1% (w/v) bromophenol blue)
and immersed in boiling water for 10 min, followed by separa-
tion on 10%-, 12%- or 15% SDS-PAGEs. Thereafter, separated
proteins were transferred in a semi-dry blotting chamber to
PVDFmembranes (GE Healthcare), followed by immunostaining
for LAP3 (diluted 1:250), Prd×1 (diluted 1:1000), Prd×6 (diluted
1:500), serum amyloid P component [SAP] (rabbit polyclonal,
abcam, diluted 1:40,000) and KRT19 (diluted 1:200) with use
of respective horseradish peroxidase-conjugated secondary anti-
bodies (DakoCytomation, Hamburg, Germany; rabbit anti-
mouse-IgG and swine anti-rabbit IgG, both diluted 1:2000). Blot
membranesweredevelopedwith theECLPlus chemiluminescent
detection system (GE Healthcare), and emitted signals were
detected with a chemiluminescence imager (Intas ChemoStar,
Intas, Göttingen, Germany). Thereafter, band intensities in
acquiredTIFF/JPEG-imageswere analyzed by densitometric scan-
ning and quantified using ImageJ software (Version 1.45 s, NIH).
For the statistical comparison of differences between two
groups (IPF vs. HV, fNSIP vs. HV and fNSIP vs. IPF) the non-
parametric Mann–Whitney U-test was applied using the
software GraphPad Prism version 4.0 (GraphPad Software
Inc., La Jolla, CA). Data are presented as mean ± SEM of the
individual values of different subjects. A p-value < 0.05 was
considered statistically significant.3. Results
3.1. Comparative proteomic analysis of IPF and fibrotic
NSIP versus Control lung tissues
For comparative proteomic profiling of IPF- (n = 14), fNSIP- (n = 8)
and control lungs (n = 10), equal protein concentrations of lung
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pooled in order to identify reproducible and robust differences.
Differential labelling with three distinct fluorescent dyes was
carried out resulting in a Cy3-labelled IPF-, a Cy5-labelled fNSIP-
and a Cy2-labelled control lung proteome. The subsequent
comparison of the fNSIP proteome with regard to the control
lung pattern revealed 26 differentially regulated proteins which
differed more than or equal to 1.5-fold, of which 14 were
upregulated (RF ≥ 1.5, Table 2) and 12 downregulated in fNSIP
(RF ≤ 0.75, Table 3). A similar regulationwasobserved for 24out of
these 26 protein spots in the comparison IPF versus controls
(Tables 2 and 3). Both tables provide information about the
identification of these differently expressed protein spots, as
well as the magnitude of difference versus the control group
(indicated asRF). Additionally, all differentially regulated proteins
for the comparison IPF- and fNSIP- versus control proteome are
depicted in the proteome map in Fig. 1A. It has to be noted that
some of the identified proteins (TPIS, KRT19, CTSD) occurred on
several positions in the 2D-gel suggesting the occurrence of
protein isoforms/variants. The isoforms/variants of one protein
were not observed in each case to be regulated in the same
manner as reflected (in part) by varying spot intensities/
RF-values.
The major part of the proteins we identified as being
upregulated in IPF and fNSIP fall into the related categories
chaperone/protein folding (PPIA), protein processing (LAP3),
energy generation/glycolysis (TPIS) and antioxidant function
(PRDX1) (Table 2), and could be all assigned also as stress-
induced genes. Genes involved in epithelial cytoskeletal orga-
nization such as cytokeratin-19 (KRT19) were also found to be
increased in IPF and fNSIP (Table 2).
3.2. Upregulated stress-induced genes in IPF and fibrotic
NSIP and their localization in lung epithelium
The accumulation of the Unfolded Protein Response (UPR)
chaperone peptidyl-prolyl cis-trans isomerase A (PPIA) wasTable 2 – Proteins significantly upregulated in IPF and fNSIP lun
Spot
no:
Accession number (NCBI)/Protein name S
E
(Z
3158 gi|11493459: PRO2619, serum albumin (ALB)
3012 gi|37588925: LAP3 protein,
Leucine aminopeptidase
3104 gi|15277503: ACTB protein
3064 gi|999892: Triosephosphate isomerase (TPIS)
2981 gi|178777: Proapolipoprotein A-1 preproprotein (APOA1BP)
3032 gi|55959887: peroxiredoxin 1 (PRDX1)
2780 gi|20149498: ferritin, light polypeptide
3550 gi|4503571: enolase 1 (ENO1)
2881 gi|24234699: keratin 19 (KRT19)
3089 gi|4501883: alpha 2 actin (ACTA2)
2922 gi|999892: Triosephosphate isomerase (TPIS)
3219 gi|1431788: Cyclophilin A, peptidylprolyl isomerase A (PPIA)
2719 No significant identification
3178 No significant identification
Definition of abbreviations: RF = regulation factor; Est´d Z: Z-score/Profoun
(p < 0.05); Seq. cov. (%) = sequence coverage in %; Theor. MW [kDa] = thevalidated by immunohistochemistry (IHC) in order to identify
the cellular distribution in fNSIP-, IPF- and control lung tissues.
In addition, we performed staining for prosurfactant protein C
(proSP-C), a protein specific to AECII, of parallel sections, in
order to designate alveolar structures in these lung tissues
(Fig. 2A–D, and O). A very strong overexpression of PPIA was
observed in AECII in areas of thickened alveolar septae in fNSIP
(Fig. 2E, F) as well as in AECII overlying dense zones of fibrotic
remodelling in IPF/UIP lungs (Fig. 2G, H), which was in contrast
to AECII in control lungs with normal histological appearance
(Fig. 2P) indicating no or only a faint PPIA expression.
Interestingly, bronchiolar basal cells (which were characterized
by cytoplasmic cytokeratin-5/KRT5 staining) in abnormal bron-
chiolar structures such as basal cell hyperplasia (Fig. 2I) or
hyperplastic bronchioles (Fig. 2J) also revealed a pronounced
expression of PPIA (Fig. 2L, M) which was only weak or barely
detectable in the basal proportion of normal lung tissues
(Fig. 2K, N). Basal cells in bronchioles of fNSIP lungs, which
have a less abnormal bronchiolar tree as compared to IPF/UIP
also showed a prominent expression of PPIA (not shown).
Fibroblastic cells revealed no or minimal immunostaining
for PPIA, whereas interstitial inflammatory cells (mast cells,
lymphocytes) in both—fibrotic and normal lung—also showed
considerable expression of PPIA (Fig. 2E–H, L–N).
Next, we went on to characterize the localization of expres-
sion of LAP3, a cytosolic leucine aminopeptidase involved in
processing of antigenic proteins [34], in the fibrotic—and normal
lung. Similar to PPIA and in line with its observed upregulation
in fNSIP and IPF (Table 2), a robust LAP3 expression was
predominantly found to co-localize with the proSP-C expression
in the AECII in areas of thickened alveolar septae in fNSIP
(Fig. 3A, B, E, F) as well as in AECII near dense zones of fibrosis in
IPF lungs (Fig. 3C, D, G, H), whereas AECII of control lungs with
normal alveolar architecture indicated a basal, lower level of
expression of LAP3 (Fig. 3M-P). No notable stainingwas observed
in fibrotic tissue itself, but inflammatory cells in the interstitium
as well as macrophages in fibrotic and normal lungs revealedgs relative to control lung tissue (RF ≥ 1.5).
core/
st´d Z
-score)
Seq. cov.
(%)
Matched
peptides
Theor.
MW
[kDa]
RF_IPF/
donor
RF_ NSIP/
donor
2.06 32 18 58.53 5.7869 5.4891
2.42 54 22 54.77 3.3611 2.4152
2.24 32 10 40.54 2.1605 2.8496
2.37 90 21 26.81 3.2599 3.8891
2.32 43 12 30.75 2.3927 2.2229
2.26 51 8 19.13 2.8129 2.7443
2.37 63 14 20.03 2.3630 3.0931
2.27 61 22 47.49 n.a. 4.6511
2.36 41 17 44.09 6.2736 6.0776
2.25 50 12 42.39 1.6950 2.1342
2.31 79 18 26.81 2.8328 3.6807
2.37 55 17 18.09 2.3102 2.1868
– – – – 6.0894 8.6522
– – – – 5.1576 4.9577
d score: a Z-score of ≥1.65 is considered significant at the 5% level
oretical molecular weight in kDa; n. a. = not applicable.
Table 3 – Proteins significantly downregulated in IPF and fNSIP lungs relative to control lung tissue (RF ≤ 0.75).
Spot
no.
Accession number (NCBII)/Protein name Score/
Est´d Z
(Z-score)
Seq. cov.
(%)
Matched
peptides
Theor.
MW
[kDa]
RF_
IPF/
donor
RF_ NSIP/
donor
2799 gi|809185: Annexin 5, ANXA5, Lipocortin V, Placental
anticoagulant protein 1 (PAP-I)
2.30 64 23 35.84 0.5296 0.5556
3170† gi|4503143: Cathepsin D preproprotein (CTSD) 2.32 34 12 45.05 0.5674 0.5717
2949 gi|576259: Serum amyloid P component (SAP) 2.30 40 8 23.35 0.5318 0.5829
3077 gi|87564: glutathione transferase (EC 2.5.1.18) (GST) 1.43 56 7 23.44 0.4891 0.5420
2854 gi|306880: preprohaptoglobin, haptoglobin (HPT) 2.11 33 8 38.95 0.6025 0.4849
2959 gi|13787109:
Alpha-1-antitrypsin (A1AT)
2.18 29 11 44.32 0.8358 0.5253
3232 Mixture: 0.8242 0.6957
1. gi|28949044: mitochondrial 2.29 52 14 54.94
Aldehyde dehydrogenase (ALDH2)
2. gi|16306550: selenium binding protein 1 (SBP1) 1.70 32 8 52.94
2907# P60709/ACTB_HUMAN:
Actin, cytoplasmic 1, beta-actin
or P63261/ACTG_HUMAN:
Actin, cytoplasmic 2, gamma-actin
124
(MOWSE score)
51 13 42.05
42.11
0.4180 0.3387
2900 gi|4557581: Fatty acid-binding protein 5 (FABP5) 1.73 58 7 15.49 0.3534 0.3883
2903* gi|5032057: S100 calcium binding protein A11 (S100A11) 2.15 87 8 11.84 0.5659 0.4155
3107 No significant identification – – – – 0.5459 0.5686
2807 No significant identification – – – – 0.4743 0.4467
Definition of abbreviations: RF = regulation factor; Est´d Z: Z-score/Profound score: a Z-score of ≥1.65 is considered significant at the 5% level
(p < 0.05); Seq. cov. (%) = sequence coverage in %; Theor. MW [kDa] = theoretical molecular weight in kDa.
† = spot migrates with MW ~ 31 kDa in 2-DE, Cathepsin D heavy chain identified; * = only identified using up to 30 kDa range;
# = identified with Mascot/Swiss-Prot database version 20110609.
Fig. 1 – Representative reference 2D-gels of 1000 μg lung proteins mapping differentially regulated proteins in (A) the
comparison fNSIP/IPF- versus Control lung proteome and (B) the comparison fNSIP- versus IPF proteome. (A) Separation of
proteins from a 1:1 mixture of the fNSIP—and Control lung proteome pool (which contained wholly all differentially protein
spots identified by precedent DIGE-image analysis) was performed on linear strips with a pH range of 4–7 followed by 16%
SDS-PAGE. The 2D-gel was stained with Coomassie. Proteins upregulated in fNSIP and IPF versus Control are indicated in italic
font, downregulated proteins are underlined. Differentially expressed protein spots which could not be successfully identified,
are indicated with n. i. (= not identified). (B) The same 2D-separation setting as shown in (A) was performed, followed by
staining of the 2D-gel with Coomassie. Proteins upregulated in fNSIP versus IPF are indicated in italic font, downregulated
proteins are underlined. Both 2D-gels were used as reference proteomes, for excising andMS identification of the differentially
regulated protein spots.
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Fig. 2 – Upregulation of peptidylprolyl isomeraseA (PPIA) expression in type-II alveolar epithelial cells (AECII) in fibrotic NSIP- and
IPF lungs. Representative immunohistochemistry for proSP-C (A–D), cytokeratin-5 [KRT5] (I, J) and PPIA (E–H, L,M) in serial sections
of fNSIP- and IPF lung tissues, and for proSP-C (O), KRT5 (K) and PPIB (N, P) in control lungs. (E, F, P) In fibrotic NSIP lungs (fNSIP),
type-II alveolar epithelial cells (AECII) in areas of thickened alveolar septae reveal strong induced expression of PPIA (E, F), in
comparison to control lungswhich indicate only faint expression of PPIA (P). (G, H, P)AECII near dense zones of fibrosis in IPF lungs
indicate upregulated expression of PPIA, when compared to control lungs. AECII are indicated by proSP-C staining (A–D) and
arrows inA–H. (L,M,N) Robust overexpressionof PPIA is also observed inbronchiolar basal cells of epithelial abnormalities suchas
basal cell hyperplasia (L) or hyperplastic bronchioles (M) in IPF lungs (indicated by cytoplasmic KRT5-staining in serial sections I
and J, and by dashed arrows in L and M), whereas basal cells of control lungs indicate only less immunoreactivity for the PPIA
antibody (N). Original magnification of photomicrographs A, C, E, G, J and M: ×200 (bar = 100 μm); original magnification of
photomicrographs B, D, F, H, I, K, L, N, O and P: ×400 (bar = 50 μm).
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Furthermore, ciliated bronchial cells (as indicated by dashed
arrows in Fig. 3I–L and parallel immunostainingwith themarker
FoxJ1 in Fig. 3K), but not non-ciliated clara cells (indicated by
CC10 staining in Fig. 3J), revealed a strong apical staining pattern
of LAP3 in IPF (Fig. 3I), fNSIP- (not shown) and control lungs
(Supplementary Fig. E4), supporting secretion of this aminopep-
tidase. Quantitative immunoblot analysis of bronchoalveolar
lavage fluids for LAP3 indicated evident extracellular appearance
of this enzyme in fNSIP-, IPF- andnormal lungs, but no statistical
significant differences between the three categories in secretion
of LAP3 (Supplementary Fig. E5).
Another stress-induced gene found to be upregulated
in fNSIP and IPF was the antioxidant protein peroxiredoxin 1
(PRDX1). By IHC, PRDX1 expression was predominantly found in
ciliated bronchial cells in IPF lungs (Fig. 4B, brown staining),
whichwere clearlymarked by nuclear FoxJ1 staining in a parallel
section (Fig. 4D), whereas non-ciliated clara cells (indicated by
CC10 staining in Fig. 4C) did not express this enzyme (Fig. 4B).
Furthermore, AECII near regions of dense fibrosis of IPF lungs
(indicated by proSP-C staining in Fig. 4A, F) revealed also nosignificant expression of PRDX1 (Fig. 4B, G), even not after
overstaining of lung tissues sections (Supplementary Fig.
E6A + B). Instead, a strong PRDX1 overexpression was observed
in alveolar macrophages (AM) of IPF—(Fig. 4G, AM are indicated
byCD68 staining in Fig. 4H) and fNSIP lungs (Supplementary Figs.
E6G + H),whereas AM in control lung tissues revealed no or faint
expression of PRDX1 (Fig. 4J, K). Similarly, AECII in control lungs
indicated nonotable or onlyweak expression of PRDX1 (Fig. 4I, J),
and only the ciliated bronchial epithelium expressed PRDX1 in
basal amounts in normal lungs (Supplementary Fig. E6T).
Interestingly andmuch to our surprise, AECII in areas of fibrotic,
thickened alveolar septae of fNSIP lungs (Fig. 4L–N) indicated a
pronounced induction and thus upregulation of PRDX1 expres-
sion (Fig. 4O–Q, indicated by arrows), and which was—similar to
our IHC results in IPF—not observed inAECII near areas of dense
uniform fibrosis in fNSIP lungs (not shown). Importantly,
fibroblastic cells or fibroblast foci did not reveal a notable
PRDX1 expression (not shown).
Due to reported appearance of PRDX1 and other
peroxiredoxins in BALF of IIP patients [35–37], we next
performedaquantitative immunoblot analysis of BALF samples
Fig. 3 – Expression analysis of leucine aminopeptidase LAP3 in lung tissue from patients with fibrotic NSIP and IPF in
comparison to Control lungs. Representative immunohistochemistry for proSP-C (A–D), LAP3 (E-I), clara cell-protein 10 [CC10]
(J), FoxJ1 (K) and cytokeratin-5 [KRT5] (L) in serial sections of fNSIP- and IPF lung tissues, and for LAP3 (M, N) and proSP-C (O, P)
in control lungs. (E, F, G, H) Type-II alveolar epithelial cells (AECII) in areas of thickened alveolar septae in fibrotic NSIP lungs
(fNSIP; E, F) as well as AECII in regions of dense fibrotic remodelling in IPF lungs (G, H) reveal robust overexpression of LAP3.
AECII are indicated by proSP-C staining (A–D) and arrows in A–H. LAP3 immunostaining is also observed in alveolar
macrophages (indicated by hashmark in G and H). (I, J, K, L) Ciliated bronchial cells in IPF lungs express also LAP3 (I), as
indicated by dashed arrows and immunostaining of serial sections with the marker protein FoxJ1 (K). Clara cells (marked by
CC10 staining in Fig. J) do not express LAP3. The same observations can be made in control lungs (not shown) (M, N) AECII of
control lungs (as indicated by proSP-C staining in parallel sections O and P) reveal a basal level of LAP3 expression. Original
magnification of photomicrographs A, C, E, G: ×200 (bar = 100 μm); original magnification of photomicrographs B, D, F, H, I–L
and M–P: ×400 (bar = 50 μm).
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for PRDX1. Representative immunoblot (Fig. 4R) and densito-
metric quantification (Fig. 4S) indicated an inconsistent and
insignificant upregulation of extracellular PRDX1 levels in BALF
of fNSIP- and IPF patients when compared to HV.
3.3. Down-regulated proteins in IPF and fibrotic NSIP
versus Control lung tissues
Among the downregulated proteins in IPF and fNSIPwere genes
crucial for cell healthiness and survival, namely antioxidants
(glutathione transferase, haptoglobin [HPT]) and anticoagulant
proteins, such as annexin A5 (ANXA5), the latter being also
involved in autophagy [38] (Table 3). Another interesting protein
found to be downregulated in IPF and fNSIP was serum amyloid
P component (SAP) which has been previously described as
an inhibitor of fibrocyte differentiation [39,40] (Table 3). We
therefore wanted to investigate the localization of biosynthesisof this very interesting enzyme in IPF-, fNSIP- and control lung
tissues by IHC, but failed due to the nature of commercially
available antibodies against SAP, which turned out to be not
suitable for IHC. Due to its reported secretion, we performed
comparative immunoblot analysis of BALF samples from IPF-,
fNSIP patients and HV for SAP. SAP protein levels were
significantly reduced in BALF from IPF patients in comparison
to HV (p < 0.05, Fig. 5A and B), and were also evidently lower in
comparison to fNSIP (without statistical significance, p = 0.1014).
Interestingly, BALF contents of SAP did not differ significantly
between the fNSIP—and HV group (Fig. 5A and B).
3.4. Differentially regulated proteins in fibrotic NSIP
versus IPF lungs and their localization in epithelium
The subsequent comparison of the fNSIP - to the IPF lung
proteome revealed 10 differentially regulated proteins which
differed more than or equal to 1.5-fold, and of which nine
Fig. 4 – Expression analysis of peroxiredoxin 1 (PRDX1) in lungs from patients with fibrotic NSIP and IPF in comparison to
Control lungs. Representative immunohistochemistry for proSP-C (A, F, L–N), PRDX1 (B, G, O-Q), clara cell-protein 10 [CC10] (C),
FoxJ1 (D), cytokeratin-5 [KRT5] (E) and CD68 (H) in serial sections of IPF- and fibrotic NSIP (fNSIP) lung tissues, and for proSP-C (I),
PRDX1 (J) and CD68 (K) in control lungs. (A–E, F–K) In IPF, PRDX1 expression is localized to ciliated bronchial cells (B) which are
indicated by FoxJ1-staining in a parallel section (D) and dashed arrows in figs. B and D. Non-ciliated clara cells (as indicated by
CC10 staining in C) don´t express PRDX1 (dashed arrows in B and C). Prominent PRDX1 overexpression is observed in alveolar
macrophages (marked by CD68 staining in H) in IPF lung tissues (indicated by hashmarks in figs. G and H), whereas AECII of IPF
lungs (which are marked by proSP-C staining in serial sections A and F) do not show any notable expression of PRDX1
(indicated by arrows in A, B, F and G). AECII and alveolar macrophages in control lungs reveal no notable PRDX1 expression
(AECII are indicated by arrows in I and J, macrophages with hashmarks in J and K). (L–Q) In contrast to AECII of IPF- and control
lungs, robust induction of PRDX1 expression is observed in AECII in areas of thickened alveolar septae in some fNSIP lungs
(indicated by arrows in L–Q). Original magnification of photomicrographs A–K, M, N, P, Q: ×400 (bar = 50 μm); original
magnification of photomicrographs L and O: ×200 (bar = 100 μm). (R) Representative immunoblot and (S) quantitative
immunoblot analysis for PRDX1 of BAL fluid from patients with sporadic fNSIP (n = 7), IPF (n = 6) and healthy volunteers
(HV, n = 6). Five μg protein of cell-free BALF samples were concentrated and separated on a 12% SDS-PAGE. Coomassie
staining of the blot membrane was used as a loading control. Intensity of bands was densitometrically quantified and
presented as column diagram for each category (mean ± SEM).
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fNSIP (RF ≤ 0.75, Table 4). Table 4 provides information about
the identification of these differently expressed protein spots,
as well as the magnitude of difference with the IPF group
(indicated as RF). As additional information, the RF values forthe relations fNSIP vs. controls as well as IPF vs. controls are
given for these spots in Table 4, because these “differentially
regulated in fNSIP vs. IPF spots” were often upregulated in
both entities relative to control lungs. For an overview, all
differentially regulated proteins for the comparison fNSIP-
Fig. 5 – Serum amyloid P component in human bronchoalveolar lavage fluid (BALF) from patients with fibrotic lung disease and
healthy volunteers. (A) Representative immunoblot and (B) quantitative immunoblot analysis for SAP of BAL fluid from patients
with sporadic fNSIP (NSIP, n = 7), IPF (n = 6) and healthy volunteers (HV, n = 6). Five μg protein of cell-free BALF samples were
concentrated and separated on a 12% SDS-PAGE. Coomassie staining of the blot membrane was used as a loading control.
Intensity of bands was densitometrically quantified and presented as column diagram for each category (mean ± SEM). *
(p < 0.05) for fNSIP versus HV.
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Fig. 1B.
Most of the proteins we identified as being upregulated in
fNSIP versus IPF appeared to be involved in defense mecha-
nisms against oxidative stress, namely antioxidants (PRDX6,
thioredoxin peroxidase B) or were activators of the proteasome
(PSME1). Genes involved in energy generation such as glycolytic
enzymes (PGAM1) were also found to be upregulated in fNSIP
relative to IPF (Table 4).
First,we investigated the expression of proteasomeactivator
complex subunit 1 (PSME1), which appeared to be upregulated
in fNSIP relative to IPF- and control lungs, and the expression of
which did not seem to differ between IPF and controls according
to the DIGE analysis (Table 4), by IHC in respective lung tissues.
AECII of thickened alveolar septae in fNSIP lungs (Fig. 6A-D)
revealed a strong induction of PSME1 (indicated by arrows in
Fig. 6E–H), and could also be encountered in AECII near moreTable 4 – Proteins significantly differentially regulated in fNSIP
RF ≤ 0.75 for downregulation.
Spot
no.
Accession number (NCBI)/Protein name
Upregulated Proteins
3175 gi|3212456: Chain A, chrystal structure of human serum albumin (
2714* gi|494296: Chain B, Cathepsin D (CTSD)
3189 gi|38566176: Phosphoglycerate mutase 1 (PGAM1)
2904 gi|5453990: proteasome activator complex subunit 1 (PSME1),
proteasome activator 28 subunit alpha (PA28 alpha), 11S regulator
complex subunit alpha
3198† gi|15277503: ACTB protein, actin beta
3191 gi|4758638: peroxiredoxin 6 (PRDX6)
2960 gi|9955007: Chain A, Thioredoxin Peroxidase B from red blood cells
3075 gi|229752: Chain B, Alpha-Ferrous-Carbonmonoxy,
Beta-Cobaltous-Deoxy-Hemoglobin (T-State)
2748 gi|229383: cytochrome b5 fragment (CYB5A)
Downregulated proteins
3072 Mixture
1. gi|14043271: keratin, type I cytoskeletal 19, cytokeratin-19 (KRT1
2. gi|16552261: unnamed protein product, vimentin (VIME)
Definition of abbreviations: RF = regulation factor; Est´d Z: Z-score/Profou
(p < 0.05); Seq. cov. (%) = sequence coverage in %; Theor. MW [kDa] = theo
* = Cathepsin D heavy chain identified; † = spot migrates with MW ~29 kdense fibrotic regions in fNSIP lungs (Suppl. Fig. E7), whereas
IPF-AECII near zones of dense fibrosis (Fig. 6I, J) or near areas
of active fibrotic remodelling (Fig. 6K) indicated no or weak
expression of this proteasomal subunit (indicated by arrows in
Fig. 6M, N, O). In some cases, a pronounced PSME1 staining was
also encountered in IPF-AECII near dense fibrotic regions (not
shown), but was nevertheless generally weaker as compared to
fNSIP lungs. Furthermore, PSME1 expression was absent in
fibroblast foci of IPF lungs (Fig. 6O). With regard to control lung
tissues, “normal” AECII indicated no significant expression of
PSME1 (see arrows in Fig. 6L, P). Finally, considerable expression
of PSME1 was generally observed in interstitial inflammatory
cells (especially lymphocytes) of fNSIP-, IPF- and control lungs
(Fig. 6M, N; Suppl. Fig. E7).
We next went on to characterize the localization of expres-
sion of peroxiredoxin 6 (PRDX6) in fNSIP-, IPF- and control lungs.
Abundant PRDX6 expressionwas observed in AECII of thickenedlungs relative to IPF lung tissue: RF ≥ 1.5 for upregulation,
Score
Est´d Z
(Z-score)
Seq.
cov.
(%)
Matched
peptides
Theor.
MW
[kDa]
RF_
NSIP/
IPF
RF_
NSIP/
donor
RF_
IPF/
donor
ALB) 2.39 36 24 68.45 1.607 2.1257 1.3218
2.35 65 16 26.46 1.596 2.3507 1.4731
2.41 76 22 28.92 1.607 3.3580 2.0911
1.91 44 12 28.88 1.583 2.2898 1.4468
2.21 38 16 40.54 1.759 5.1477 2.9279
2.32 70 15 25.13 1.544 1.5162 0.9823
2.37 66 20 21.68 1.521 0.6125 0.4014
2.40 99 15 15.96 1.618 1.5674 0.9703
1.66 87 7 10.01 1.825 3.5195 1.9309
9) 2.16
2.34
57
33
32
14
44.07
47.53
0.463 3.0437 6.5791
nd score: a Z-score of ≥1.65 is considered significant at the 5% level
retical molecular weight in kDa.
Da in 2-DE.
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and E–F), and in AECII near zones of dense fibrosis in IPF
lungs (indicated by arrows in Figs. 7C–D and G–H), as well as
in “normal” AECII of control lungs (indicated by arrows in
Fig. 7M-P). Additionally, robust expression of PRDX6 was
observed in ciliated bronchial cells in IPF lungs (indicated by
dashed arrows in Fig. 7I-K), but not in non-ciliated clara cells
(indicated by CC10 staining in Fig. 7J). The same observationwas
made in bronchioles of fNSIP lungs (not shown) and control
lungs (Fig. 7M). Fibroblastic cells of IPF lungs did not reveal
pronounced expression of PRDX6, whereas some inflammatory
cells in the interstitium of fNSIP-, IPF- and control lungs
indicated considerable PRDX6 expression. However, differences
in cellular expression of PRDX6 could not be observed in IHC,
possibly due to high abundance of this enzyme in the human
lung [41]. Immunoblot analysis of BALF samples for PRDX6
revealed reducedprotein levels in fNSIP and IPF in comparison to
HV, but PRDX6-protein contents were still higher in fNSIP when
compared to IPF (Fig. 7Q and R). However, these results were not
statistically significant.
Finally, we focused our research on cytokeratin-19 (KRT19),
which occurred on several positions in the 2D-gel, thereby
indicating different fold changes/RF-values in the comparisonsFig. 6 – Induction and upregulation of proteasome activator comp
in fibrotic NSIP lungs. Representative immunohistochemistry for
fNSIP- and IPF lung tissues, and for proSP-C (L) and PSME1 (P) in
septae in fibrotic NSIP lungs (fNSIP; A–D) reveal robust expressio
dense fibrosis (I, J) and active fibrotic remodelling (K) indicate no
(L, P) AECII of control lungs indicate no significant expression of
also found in some interstitial inflammatory cells in fNSIP, IPF- a
photomicrographs A, C, E, G, I, M: ×200 (bar = 100 μm); original m
(bar = 50 μm).IPF/fNSIP versus controls (Fig. 1A and B, Tables 2 and 4). First,
one KRT19 spot appeared to be equally upregulated in fNSIP-
and IPF- versus control lungs according to the DIGE analysis
(Fig. 1A, Table 2). Further, KRT19 protein was identified in a
protein spot containing a mixture of KRT19 and vimentin
(VIME), presumably due to comigration as a result of the similar
MW and pI (isoelectric point) of both proteins (indicated in
Fig. 1B and Table 4). This spot appeared to be upregulated in IPF-
and fNSIP- relative to control lungs, andwas nevertheless twice
asmuch downregulated in fNSIP- relative to IPF lungs according
to the DIGE analysis (Table 4). We therefore investigated the
localization of KRT19 expression in fNSIP-, IPF- and control
lungs by IHC. KRT19 was expressed in an induced fashion in
AECII of thickenend alveolar septae (Fig. 8A, E) and in AECII
overlying areas of uniform dense fibrosis in fNSIP lungs
(Fig. 8B, F), as well as in AECII near areas of fibrotic remodelling
and bronchiolization in IPF lungs (Supplementary Fig. E8). In
contrast, “normal” AECII of control lungs indicated only faint
expression of KRT19 (Fig. 8C, G). In IPF/UIP lungs, KRT19
overexpression was (beside AECII) strikingly evident in bron-
chial structures (bronchiolar basal cells and ciliated and non-
ciliated bronchial cells, see Fig. 8D) in areas of bronchiolization
and honeycomb cyst formation, which are indicated by KRT5lex subunit 1 (PSME1) in type-II alveolar epithelial cells (AECII)
proSP-C (A–D, I–K) and PSME1 (E–H, M–O) in serial sections of
control lungs. (A–D, E–H) AECII in areas of thickened alveolar
n of PSME1 (see arrows in E–H). (I–K, M–O) AECII near areas of
or only sparse PSME1 expression (see arrows in M, N and O).
PSME1 (indicated by arrows). In general, PSME1 expression is
nd control lungs (G, M–P). Original magnification of
agnification of photomicrographs B, D, F, H, J–L, N–P: ×400
Fig. 7 – Expression analysis of peroxiredoxin 6 (PRDX6) in lungs from patients with fibrotic NSIP and IPF in comparison to
Control lungs. Representative immunohistochemistry for proSP-C (A–D), PRDX6 (E–H, I), clara cell-protein 10 [CC10] (J), FoxJ1
(K) and cytokeratin-5 [KRT5] (L) in serial sections of fNSIP- and IPF lung tissues, and for PRDX6 (M, N) and proSP-C (O, P) in
control lungs. (A–D, E–H) AECII in areas of thickened alveolar septae in fibrotic NSIP lungs (fNSIP; A, B, E, F) as well as AECII near
zones of dense fibrosis in IPF lungs (C, D, G, H) reveal robust expression of PRDX6 (indicated by arrows). (I–L) In IPF lungs, PRDX6
expression is also found in ciliated bronchial cells which are marked by FoxJ1-staining in a parallel section (K) and dashed
arrows in Figs. I, J and K. Non-ciliated clara cells (as indicated by CC10 staining in J) don´t express PRDX6 (I and J). Moderate
PRDX6 expression is also observed in some bronchiolar basal cells in IPF lungs (indicated by KRT5-staining in L and
arrowheads in I and L). (M–P) In control lungs, PRDX6 is robustly expressed in AECII (indicated by arrows) and ciliated bronchial
cells (indicated by dashed arrows). Original magnification of photomicrographs A, C, E, G: ×200 (bar = 100 μm); original
magnification of photomicrographs B, D, F, H, I–L and M–P: ×400 (bar = 50 μm). (Q) Representative immunoblot and
(R) quantitative immunoblot analysis for PRDX6 of BAL fluid from patients with sporadic fNSIP (n = 7), IPF (n = 6) and healthy
volunteers (HV, n = 6). Five μg protein of cell-free BALF samples were concentrated and separated on a 15% SDS-PAGE.
Coomassie staining of the blot membrane was used as a loading control. Intensity of bands was densitometrically quantified
and presented as column diagram for each category (mean ± SEM).
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(Fig. 8H). Immunoblot analysis of BALF samples for KRT19
revealed significantly enhanced protein contents of a ~25 kDafragment in lavages of IPF patients, in comparison to fNSIP and
HV (p < 0.05 vs. fNSIP; p < 0.01 vs. HV; Fig. 8I and J). Despite
reportedevidenceofCYFRA (cytokeratin 19 fragment, ~37 kDa) in
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well as full-length KRT19 (~44 kDa) in concentrated lavage
samples (10 μg) obtained from our IIP patient cohort.
3.5. Alveolar epithelial endoplasmic reticulum (ER) stress
in fibrotic NSIP and IPF
We observed induced expression of stress-induced genes PPIA
and LAP3 in AECII of lungs from fNSIP- and IPF patients, as well
as encountered induced expression of the antioxidant enzyme
PRDX1 and the proteasome activator PMSE1 predominantly in
the AECII of fNSIP lungs. Therefore, we finally investigated the
localization of expression of typical UPR/ER stress-marker (and
-sensor) proteins suchas activating transcription factor 6 [ATF6,
including activated p50ATF6(N)] and X-box binding protein 1
(XBP1) in fNSIP- in comparison to IPF- and control lungs. AECII
near dense zones of uniform fibrosis in fNSIP lungs (Fig. 9A, B) as
well as AECII in areas of dense fibrotic remodelling in IPF/UIP
lungs (Fig. 9D) indicated robust induction of p50ATF6/ATF6Fig. 8 – Expression analysis of cytokeratin 19 (KRT19) in lungs from
lungs. Representative immunohistochemistry for cytokeratin 19
and for KRT19 (C) and proSP-C (G) in control lung tissues, and for
In fNSIP, robust KRT19 overexpression was observed in hyperpl
AECII in areas of dense uniform fibrosis (B, F). (C, G) AECII in contr
by arrows), whereas bronchial epithelium reveal a notable consti
hashmark in C). (D, H) In IPF lungs, strong expression of KRT19 is
very dominantly in bronchiolar basal cells (indicated by KRT5 sta
cells of abnormal bronchioles in bronchiolized areas in IPF lungs
(bar = 200 μm); original magnification of photomicrographs B an
photomicrographs C and G: ×400 (bar = 50 μm); original magnifi
(I) Representative immunoblot and (J) quantitative immunoblot a
fNSIP (n = 7), IPF (n = 6) and healthy volunteers (HV, n = 6). 10 μg
separated on a 10% SDS-PAGE. Coomassie staining of the blot me
densitometrically quantified and presented as column diagram f
HV, ** (p < 0.01) for IPF versus HV.(Fig. 9E, F, H) andXBP1 (Fig. 9I, J, L) to sameextent, in comparison
to “normal” AECII of control lungs which revealed no or only
sparse expression of ATF6 or XBP1 (Fig. 9M, N, O). Induced and
considerable overexpression of p50ATF6/ATF6 and XBP1 was
also observed in AECII in areas of thickened alveolar septae of
fNSIP lungs (Fig. 9C, G, K). Alveolar macrophages of fNSIP- and
IPF lungs revealed also immunostaining for ATF6 (Fig. 9E, F, H),
but not for XBP1 (Fig. 9I, J, L).4. Discussion
We performed a comparative proteome analysis of lung tissue
from patients with fNSIP and IPF and normal control lung tissue
in order to identify differentially regulated proteins in fNSIP and
IPF relative to controls as well as between IPF and fNSIP itself.
The latter aim was challenging, because it had been reported
that gene expression profiles of IPF- and NSIP lungs were quite
similar and that only few differences between the two types ofpatients with fibrotic NSIP and IPF in comparison to Control
[KRT19] (A, B) and proSP-C (E, F) in fibrotic NSIP lungs (fNSIP),
KRT19 (D) and cytokeratin 5 [KRT5] (H) in IPF lungs. (A, B, E, F)
astic AECII in areas of thickened alveolar septae (A, E) and in
ol lungs indicate a weak basal expression of KRT19 (indicated
tutive KRT19 expression in normal control lungs (indicated by
not only observed in hyperplastic AECII (not shown), but also
ining in H), as well as ciliated—and non-ciliated bronchial
. Original magnification of photomicrographs A and E: ×100
d F: ×200 (bar = 100 μm); original magnification of
cation of photomicrographs D and H: ×50 (bar = 500 μm).
nalysis for KRT19 of BAL fluid from patients with sporadic
protein of cell-free BALF samples were concentrated and
mbrane was used as a loading control. Intensity of bands was
or each category (mean ± SEM). * (p < 0.05) for fNSIP versus
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proteomeswas overcome by the 2D-DIGEmethod, by separating
and comparing the differently labelled IPF-, fNSIP- and healthy
control lung proteome (IPF: Cy3, NSIP: Cy5, control: Cy2) on
one and the same 2D-gel. Spot matching and quantification
were improved in comparison with traditional 2D-gel-based
techniques.
Our study is limited by the relatively low number of lung
tissue samples for each patient category, especially for fNSIP
and donor lung materials. It has, however, to be kept in mind,
that both, IPF and fNSIP, are orphan diseases, with (idiopathic)
fNSIP being even much less frequent as compared to IPF. To
somewhat circumvent this problem, we used pooled samples
of organ donor lungs as well as of explanted end-stage lungs
from each patient category, in order to reduce the (everlasting)
biological variation from patient to patient, and to identify
robust and “real” differences. In addition, most of the relevant
results/proteomic signatures were further confirmed by
IHC in individual samples, and by additional analysis of
BALF obtained from additional IPF- and fNSIP patients. WeFig. 9 – Induction of markers for the Unfolded Protein Response (
and IPF lungs. Representative immunohistochemistry for proSP-
X-box binding protein 1 [XBP1] (I–L) in serial sections of fNSIP- an
(0) in control lungs. (A–D), (E–H), (I–L) AECII in areas of dense unifo
as AECII in areas of active fibrotic remodelling in IPF lungs (D, H,
extent (AECII are indicated by arrows). Alveolar macrophages of
expression of ATF6 (F and H), but not of XBP1 (J and L). Expressio
thickened alveolar septae in fNSIP lungs (see arrows in C, G, K). (M,
XBP1 is observed in the AECII (indicated by arrows). Original magn
original magnification of photomicrographs B–D, F–H, J–L: ×400 (batherefore believe that inclusion of a larger number of samples
would not greatly change our findings and conclusions.
In linewith previously performed transcriptional profiling of
IPF and NSIP lungs [10,11,31], our results certainly indicate that
both diseases are “proteomically" similar, suggesting similar
pathogenetic principles and disease processes. In accordance
with our previous published proteome analysis of IPF- and
control lungs [33], thepresent data set certainly suggests that ER
stress as well as a general stress-response play a crucial role in
the pathogenesis of both IPF and fNSIP. Among the upregulated
proteins in IPF and fNSIP were stress-induced proteins, such as
leucine aminopeptidase (LAP3) and peptidylprolyl isomerase A
(PPIA), the latter being also described to be involved in the UPR
[44]. With its chaperone and PPIase activities, PPIA ascertains
the correct folding and conformation of nascent or denaturated
proteins, and also provides protection against environmental
insults. LAP3 has been reported to catalyze the initial processing
of antigenic proteins in the cytoplasm,which is a necessary step
for antigen presentation and recognition by cytotoxic T lym-
phocytes (CTLs) [34]. As expected, both stress-induced genesUPR) in type-II alveolar epithelial cells (AECII) in fibrotic NSIP
C (A–D), activating transcription factor 6 [ATF6] (E–H) and
d IPF lung tissues, and for proSP-C (M), ATF6 (N) and XBP1
rm fibrosis in fibrotic NSIP lungs (fNSIP; A, B, E, F, I, J) as well
L) reveal very strong expression of ATF6 and XBP1 to same
fNSIP and IPF lungs (indicated by hashmarks) reveal also
n of ATF6 and XBP1 is also observed in AECII in areas of
N, O) In control lungs, no or only sparse expression ofATF6 and
ification of photomicrographs A, E, I: ×200 (bar = 100 μm);
r = 50 μm).
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in the fibrotic lung: AECII of thickened alveolar septae and near
areas of dense uniform fibrosis in fNSIP lungs as well as AECII
near dense fibrotic regions inUIP/IPF lungs showed robust PPIA-
or LAP3 expression, whereas “normal” AECII of control lungs
indicated no or only a basal, lower expression of both enzymes
(Figs. 2 and 3). Importantly, PPIA expression is not only induced
by the UPR, but also induced in response to a wide variety of
stressors including cancer [45]. PPIA is upregulated in many
cancers [45,46], and probably functions in maintaining the
conformation of oncogenic proteins. It has also been suggested
that PPIA exerts in tumor cells an anti-apoptotic function by
sequestering cytochrome c [47]. Upregulation of PPIA was also
observed in “abnormal” bronchiolar basal cells of IPF lungs, but
not in the basal layer of normal bronchioles in control lungs
(Fig. 2I–N). We suggest that induced overexpression of PPIA in
basal cells may be one cause for the (observed) exaggerated,
proliferative character of this cell type in IPF and thus govern
the process of bronchiolization in this disease.
As expected, antioxidant enzymes such as peroxiredoxin 1
(PRDX1) were observed to be upregulated in fNSIP and IPF,
presumably as a response to (reported) increased oxidative
stress in IIP´s [48–50]. Moreover, it has recently been shown that
homozygous Prdx1(−/−) knockout mice are more susceptible to
bleomycin-induced lung fibrosis in comparison towild-typmice,
with marked increases in pulmonary ROS levels in diseased
knockout mice, thus underscoring the crucial role of Prdx1 in
protection against pulmonary fibrosis because of its antioxidant
actions [51]. For validation of upregulated PRDX1 expression, we
analyzed its cellular distribution in fNSIP-, IPF- and normal
control lungs by IHC. Interestingly, we found PRDX1 to bemainly
expressed in ciliated bronchial cells and inalveolarmacrophages
in fNSIP-, IPF- and control lungs (with pronounced upregulation
in fNSIP- and IPF lungs vs. controls), whereas “hyperplastic”
AECII in IPF- as well as “normal” AECII in control lungs did not
reveal a notable expression of PRDX1 (Fig. 4A–K). Much to our
surprise, we observed a prominent induction of PRDX1 in
hyperplastic AECII in areas of thickened alveolar septae in
some fNSIP lungs (Fig. 4L–Q, Suppl. Fig. E6I-P). Of note,
“hyperplastic” AECII near areas of dense uniform fibrosis in
fNSIP lungs did—similar to the AECII of UIP/IPF lungs—never
reveal a significant PRDX1 expression. Taken together, the
impressive finding of an AECII-localized upregulation of PRDX1
exclusively in NSIP-typical areas such as thickened alveolar
septae in fNSIP lungsmay represent anattempt by theseAECII to
adjust to the microenvironment in a manner that is advanta-
geous to survival. According to this notion, induction of ER stress
sensed by the ATF6 and IRE1/XBP1-pathways was also encoun-
tered inAECII in areas of thickened alveolar septae in fNSIP lungs
(Fig. 9). Oxidative stress is known to disrupt protein folding
through formation of protein carbonyls; and oxidative stress
and ER stress-response are tightly interconnected through
the PERK/Nrf2 pathway which induces cytoprotective and
antioxidant acting genes such as peroxiredoxins in response to
increased ROS levels and oxidant stress [52,53]. Furthermore, it
has been already shown that Nrf2 is induced and upregulated in
AECII of both NSIP- and IPF lungs, whereas “normal” AECII in
controls did not indicate notable protein levels of this transcrip-
tion factor [49,54]. Additionally, antioxidants have been reported
to reduce ER stress and improve protein secretion in an in vitromodel of protein misfolding [55]. Although purely speculative at
present, the observed upregulation of PRDX1 exclusively inAECII
in areas of thickened alveolar septae in fNSIP lungs could
represent a protection- and survival mechanism of these AECII
against oxidant-mediated cell injury and apoptosis, thereby
resulting in preservation of septated alveolar structure in this
histologic subtype.
Among the down-regulated proteins in fNSIP and IPF
(Table 3), we identified the anti-coagulant protein annexin A5
(ANXA5), consistent with the decreased fibrinolytic activity in
ILD [56]. ANXA5 is also involved in autophagosomematuration
and thus directly in autophagy which is a pathway responsible
for the degradation of unwanted intracellular materials. There-
fore, ANXA5 is crucial for cell survival [38,57]. In line with
reported oxidant-antioxidant imbalance in IIP´s [50], we ob-
served a downregulation of some antioxidant acting enzymes,
namely glutathione transferase and haptoglobin. Haptoglobin
is a hemoglobin-binding acute-phase protein which possesses
anti-inflammatory and antioxidative properties. Haptoglobin
decreases hemoglobin-driven oxidative stress: It forms a
complex with hemoglobin in order to protect the organs from
damage by hemoglobin, while making the hemoglobin accessi-
ble to degradative enzymes [58,59].
Another very interesting downregulatedprotein in fNSIP and
IPF was serum amyloid P component (SAP), a member of the
pentraxin family, andwhichhas been shown to inhibit fibrocyte
differentiation in vitro [39,40]. In line with this observation, SAP
has been recently described to reduce bleomycin-induced lung
fibrosis in themouse throughattenuating bonemarrow-derived
mesenchymal cell accumulation and collagen synthesis [60].
Additionally, SAP has been also shown to inhibit profibrotic
alternative (M2) macrophage activation and accumulation in
models of pulmonary and renal fibrosis [61,62]. Another
function of SAP is to scavenge nuclear material (i. e. DNA)
from damaged circulating cells and to clear apoptotic and
necrotic cell debris [63,64]. Interestingly, our analysis of
BALF-SAP protein contents revealed significantly reduced
protein levels for IPF only, as compared to healthy volunteers
(HV), whereas BALF of fNSIP patients contained SAP levels
similar to HV (Fig. 5)—the latter finding being in contrast to the
DIGE results employing lung tissue (Table 3). On the other hand,
this result is in line with reduced or no appearance of fibroblast
foci in fNSIP and suggests, that BALF-SAP levelsmaydistinguish
IPF/UIP from other IIPs. Moreover, measuring of circulating
levels of SAP in plasma samples has been recently undertaken
in IPF patients and HV [65], indicating significantly reduced SAP
concentrations in the circulation of IPF patients. Moreover,
reduced SAP plasma levels predicted disease progression
measured by the change in FVC (forced vital capacity) in IPF
[65]. Similarly, BALF-SAP levels might also predict disease
progression and severity in IPF, fNSIP, EAA and other IIP and
could thus be used in the future as an additional diagnostic tool.
Finally, we identified only a few proteins that were
differentially expressed between fNSIP and IPF. Among the
significantly upregulated proteins in fNSIP versus IPF were the
antioxidant acting proteins PRDX6 and thioredoxin peroxidase B
(Table 4), suggesting that the increase of antioxidant activity is
correlated to survival and better outcome and that a decline of
antioxidant capacity correlates with disease progression.
Another interesting, upregulated protein in fNSIP was PSME1
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of the proteasome implicated in antigen processing [34].
Recently, PSME1 has also been suggested to improve clearance
of misfolded, oxidized proteins. Whereas overexpression of
PSME1 in vitrowas found to significantly attenuate H2O2-induced
accumulation of protein carbonyls and apoptosis in cultured
cardiomyocytes [66], the reverse approach, knockdown of PSME1
in vitro, forwarded enhanced susceptibility to oxidant cell injury
[67]. Similar to conventional antioxidant enzymes such as
peroxiredoxins or glutathione transferase, PSME1 is also a target
of the cytoprotective antioxidant transcription factor Nrf2, and
induced in response to oxidative stress [68]. Only recently,
induction of proteasome activator complex subunit 1 was also
shown to be involved in the removal ofmodified proteins during
the process of differentiation [69]. Thus, the observed induction
of PSME1 in AECII in areas of thickened alveolar septae in fNSIP
lungs (Fig. 6)may contribute to improved cellular survival in this
disease.
Peroxiredoxin 6 (PRDX6) is the isoform (out of all six
mammalian peroxiredoxins) expressed at the highest level and
its lung expression exceeds that for other organs [41]. PRDX6 has
several properties that distinguish its peroxidase activity from
other peroxiredoxins: First, it can reduce phospholipid hydro-
peroxides in addition to other organic hydroperoxides and
H2O2. Second, PRDX6 uses GSH as an electron donor—and not
thioredoxin—to reduce hydroperoxides. Third, PRDX6 has also a
(Ca2+-independent) phospholipase A2 activity which plays an
important role in lung surfactant homeostasis and is responsible
for degradation of internalized dipalmitoylphosphatidylcholine
[41]. Transgenic mice overexpressing Prdx6 have increased
defense against lung injury induced by hyperoxia, whereas
Prdx6(−/−) knockout mice were more sensitive to the toxic effects
of hyperoxia or paraquat [70,71]. Other studieswith homozygous
Prdx6(−/−) knockoutmice indicated that lack of Prdx6 exaggerates
lipopolysaccharide-induced acute lung injury and inflammation
with increased oxidative stress [72]. Furthermore, lens epithelial
cells isolated from Prdx6(−/−) knockout mice had enhanced
expression of ER stress response genes, were sensitive to
oxidative stress, and showed abnormal phenotypes with spon-
taneous apoptosis [73].
With regard to our DIGE data, we observed a significant
upregulation of PRDX6 in fNSIP compared to IPF and controls,
with no changes in PRDX6 expression between IPF and controls
(Table 4). Using IHC, a very strong expression of PRDX6 was
encountered in AECII of fNSIP-, IPF- and control lungs to similar
extent (Fig. 7); and it could not be differentiated between PRDX6
expression in AECII of thickened alveolar septae and AECII
overlying areas of dense fibrosis, presumably due to its particu-
larly high level in lung.
A protein spot containing KRT19 and vimentin (VIME) due
to comigration as a result of similar MW and pI of both
proteins was the onliest significantly downregulated spot in
fNSIP versus IPF, but was upregulated in both fNSIP and IPF
relative to controls (Table 4). Since vimentin is a cytoskeletal
protein associated with the function of fibroblasts, its reduced
expression in fNSIP- versus IPF lungs was conceptional, due to
generally reduced tissue fibrosis in NSIP. With regard to KRT19,
we validated its downregulation via IHC. KRT19 is a specific
cytoskeletal structure protein for simple-type epithelia, includ-
ing bronchial and alveolar epithelial cells (BAEC). In fNSIP,KRT19expressionwas robustly expressed in an induced fashion
in hyperplastic AECII compared to normal AECII in control
lungs, and was dominating in AECII in fNSIP lungs. In UIP/IPF
lungs, KRT19 expression was certainly found in AECII, but was
also particularly dominating in basal and luminal bronchiolar
cells in areas of bronchiolization, including epithelial abnor-
malities such as squamous metaplasia lining the honeycomb-
regions (Fig. 8, Suppl. Fig. E8). Thus, KRT19 upregulation in IPF
versus fNSIPhighlighted thephenomenonof aberrant epithelial
repair in IPF such as the bronchiolization-process which is
a hallmark of the UIP pattern [1,3,15,17]. In line with this,
increased BALF and serum levels of cytokeratin 19 fragment
(CYFRA) have been reported to reflect ongoing epithelial injury
and repair in IPF [42,43]. However, we could not detect CYFRA or
full-length KRT19 in concentrated lavage samples by immuno-
blotting. Instead, we observed significantly elevated protein
levels of a ~25 kDa fragment of KRT19 in BALF of IPF patients in
comparison to fNSIP and HV [Fig. 8I, J], possibly reflecting only
the process of epithelial instability and apoptosis in IPF, but not
extensive regeneration of epithelial cells. KRT19 has been
described as a caspase-3 substrate [74,75] and is cleaved by it
in response to induction of apoptosis by anisomycin [76].
Taken together, our DIGE data including validation experi-
ments suggest that there are consistent, but only few differences
between IPF and fNSIP at the proteomic level. In comparison to
IPF, the proteomic signature of fNSIP was enriched for genes
which are functionally associated with defense mechanisms
against oxidative—and ER stress and thus antiapoptotic strate-
gies. Importantly, this finding is in line with the reported
transcriptomic signature inNSIP lungs, revealing downregulation
of the proapoptotic p53 kinase HIPK2 in this entity versus IPF
lungs—and thus reduced apoptosis in NSIP. With regard to
normal control lungs, HIPK2 was upregulated in both NSIP and
IPF [10]. Additionally, the obtained fNSIP signature of increased
antioxidant capacity in alveolar epithelium is in line with
previous IHC-studies reporting decreased expression of apoptotic
proteins (p53, p21) in (alveolar) epithelial cells of NSIP- in
comparison to IPF lungs [23,24]. We therefore conclude that the
impressive finding of an AECII-localized upregulation of antiox-
idant acting enzymes aswell as of factors involved in the removal
of oxidized proteins in fNSIP lungs may represent an attempt of
these AECII to survive under conditions of persistent ER- and
oxidative stress (Fig. 10), thereby resulting in the maintenance of
septated alveolar structure in this distinct histologic subtype.
Taken together, our data indicate that central molecular
events in the pathogenesis of IPF and fNSIP are localized to
the alveolar epithelium, and put forward antioxidant thera-
peutic approaches to inhibit detrimental oxidant-mediated
reactions (which may also originate from chronic ER stress) in
these fatal diseases.
4.1. Correlation of proteomic changes with functional data
With regard to SAP, we performed a linear regression analysis
between SAP-BALF levels and DLCO/SB values from fNSIP-
and IPF patients, and observed no significant correlation of
SAP-BALF levels with DLCO/SB [Suppl. Fig. E9B]. Importantly,
we observed a significant correlation of BALF-SAP with DLCO
(r2 = 0.50, p = 0.0224) when IPF patients and HV were included
in the analysis [Suppl. Fig. E9C]. Further linear regression
Fig. 10 – Oxidant-mediated injury and thedeclineof antioxidant
capacity are key in the pathogenesis of fibrotic NSIP and IPF.
The scheme depicts a unifying pathomechanistic concept
underlying sporadic fibrotic NSIP (fNSIP) and IPF, indicating
epithelial injury as the triggering event. Oxidative stress
originating from exogenous “second hits” such as inhalative
noxes (smoking, air pollution) or from endogenous ER stress is
disease-determinant, and triggers and results in increased
AECII apoptosis and fibrosis. In fNSIP, signatures of enhanced
protection mechanisms against oxidative—and ER stress in
alveolar epitheliumdistinguish this disease from IPF, andmight
explain the better outcome and survival in that entity. AECII
are indicated by proSP-C staining in photomicrographs,
bar = 200 μm. Abbreviations: ROS = reactive oxygene species;
AECII = type-II alveolar epithelial cell; FF = fibroblast foci;
PRDX-1,-6 = peroxiredoxin 1 and -6, PSME1 = proteasome
activator complex subunit 1.
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correlate with DLCO/SB in patients with fNSIP and IPF [Suppl.
Figs. E10/E11A–C], and BALF contents for 25 kDa-KRT19
fragment displayed a significant inverse correlation with
DLCO/SB in both categories [Suppl. Figs. E12A + C]. Addition-
ally, BALF levels of PRDX6 and KRT19 fragments also
correlated significantly with FVC in IPF patients [Suppl. Figs.
E13A + B]. Despite the low number of patient subjects used for
analyses, these preliminary correlation tests might suggest a
biological relationship between SAP, PRDX1 and -6, and
cleaved KRT19 fragments with the severity of lung disease in
IPF and/or fNSIP.
Hence, these correlation studies offer “antioxidant” (PRDX1
and -6) or “antifibrotic” (SAP) signatures as novel biomarkers to
monitor disease progression and severity in different IIPs. Future
research should focus on confirming these findings and
suggestions in BALF and serum in a bigger cohort of IPF- and
fNSIP patients, and if this panel of proteins may be used to
differentiate IPF from NSIP (and also from other IIPs), and to
indicate prognosis.5. Concluding remarks
In conclusion, we demonstrated for the first time a comparative
proteome analysis of subpleural lung tissue from patients with
sporadic IPF and fNSIP, with explanted donor lungs serving as
controls. We observed that the histologically different pre-
sentations of UIP/IPF and fNSIP were proteomically similar and
that only few protein expression changes exist between IPF and
fNSIP. Our data suggest that ER stress and a general stress–
response as well as the decline of antioxidant capacity in
alveolar epitheliumare key in the pathogenesis of IPF and fNSIP.
Finally, we conclude that signatures of enhanced protection
mechanisms against oxidative—and ER stress distinguish fNSIP
from IPF, and may explain the better outcome and survival in
patientswith fNSIP in comparison to IPF patients (Fig. 10). These
changes seem to be correlated with disease severity.
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